{"transactions":[{"id":1259822,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":83058,"kind":"person","name":"Naftzger J. Christopher","position":1,"cik":"0001496194","reported_name":"Naftzger J. Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-19T18:25:53.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":220300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date."}],"balance_after":220300,"derivative":{"exercise_price":3.29,"expiration_date":"2035-02-14","underlying":"Common Shares","underlying_shares":220300},"source":{"system":"sec-edgar","filing":"0001447028-25-000052","document":"wk-form4_1740007544.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1496194/000144702825000052/wk-form4_1740007544.xml","form_type":"4"}},{"id":1259821,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":83058,"kind":"person","name":"Naftzger J. Christopher","position":1,"cik":"0001496194","reported_name":"Naftzger J. Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Common Shares","published_at":"2025-02-19T18:25:53.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":54300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction."}],"balance_after":140544,"source":{"system":"sec-edgar","filing":"0001447028-25-000052","document":"wk-form4_1740007544.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496194/000144702825000052/wk-form4_1740007544.xml","form_type":"4"}},{"id":1281823,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":83058,"kind":"person","name":"Naftzger J. Christopher","position":1,"cik":"0001496194","reported_name":"Naftzger J. Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Common Shares","published_at":"2025-02-05T16:02:16.000Z","date":"2025-02-04","kind":"sale","planned":true,"acquired":false,"shares":11333,"price":3.283,"value":37206.239,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the non-discretionary sale of common shares pursuant to the Reporting Person's 10b5-1 Plan, adopted on July 11, 2023, to satisfy the Reporting Person's tax obligations with respect to the vesting of previous grants of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,214 and 1,263 shares acquired under the Arbutus Biopharma Corporation 2020 Employee Stock Purchase Plan on February 29, 2024 and August 30, 2024, respectively."}],"balance_after":86244,"source":{"system":"sec-edgar","filing":"0001447028-25-000037","document":"wk-form4_1738789328.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496194/000144702825000037/wk-form4_1738789328.xml","form_type":"4"}},{"id":1658799,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":83058,"kind":"person","name":"Naftzger J. Christopher","position":1,"cik":"0001496194","reported_name":"Naftzger J. Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-05T19:55:14.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":380500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date."}],"balance_after":380500,"derivative":{"exercise_price":2.4,"expiration_date":"2034-02-01","underlying":"Common Shares","underlying_shares":380500},"source":{"system":"sec-edgar","filing":"0001447028-24-000029","document":"wk-form4_1707180904.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1496194/000144702824000029/wk-form4_1707180904.xml","form_type":"4"}},{"id":1658798,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":83058,"kind":"person","name":"Naftzger J. Christopher","position":1,"cik":"0001496194","reported_name":"Naftzger J. Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Common Shares","published_at":"2024-02-05T19:55:14.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":95100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction."}],"balance_after":95100,"source":{"system":"sec-edgar","filing":"0001447028-24-000029","document":"wk-form4_1707180904.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496194/000144702824000029/wk-form4_1707180904.xml","form_type":"4"}},{"id":1830920,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":83058,"kind":"person","name":"Naftzger J. Christopher","position":1,"cik":"0001496194","reported_name":"Naftzger J. Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-12T16:12:29.000Z","date":"2023-07-10","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects the closing price of the Issuer's common shares on the Nasdaq Stock Market on July 10, 2023, the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date."}],"balance_after":500000,"derivative":{"exercise_price":2.26,"expiration_date":"2033-07-10","underlying":"Common Shares","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001447028-23-000066","document":"wk-form4_1689192740.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496194/000144702823000066/wk-form4_1689192740.xml","form_type":"4"}},{"id":2185623,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":83058,"kind":"person","name":"Naftzger J. Christopher","position":1,"cik":"0001496194","reported_name":"Naftzger J. Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Corp Sec"}}],"security":"Phantom Shares","published_at":"2022-08-15T20:39:35.000Z","date":"2022-08-11","kind":"exercise","acquired":true,"shares":31600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The restricted stock units (\"RSU\") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( \"Phantom Shares\"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares."},{"field":"date","element":"transactionDate","label":"F3","text":"The restricted stock units (\"RSU\") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( \"Phantom Shares\"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Subject to the reporting person's continued employment with the Issuer, the Phantom Shares will vest in equal annual installments over four years with the first installment vesting on January 28, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Subject to the reporting person's continued employment with the Issuer, the Phantom Shares will vest in equal annual installments over four years with the first installment vesting on January 28, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The restricted stock units (\"RSU\") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( \"Phantom Shares\"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The restricted stock units (\"RSU\") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( \"Phantom Shares\"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares."}],"balance_after":31600,"derivative":{"underlying":"Ordinary Shares","underlying_shares":31600},"source":{"system":"sec-edgar","filing":"0001104659-22-091488","document":"tm2222534-17_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1496194/000110465922091488/tm2222534-17_4seq1.xml","form_type":"4"}},{"id":2185622,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":83058,"kind":"person","name":"Naftzger J. Christopher","position":1,"cik":"0001496194","reported_name":"Naftzger J. Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Corp Sec"}}],"security":"Stock Appreciation Right","published_at":"2022-08-15T20:39:35.000Z","date":"2022-08-11","kind":"exercise","acquired":true,"shares":63200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the \"2022 AGM\") of Nabriva Therapeutics plc (the \"Issuer\"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the \"2022 AGM\") of Nabriva Therapeutics plc (the \"Issuer\"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person's continued employment with the Issuer, the cash-settled share appreciation right will vest over a four-year period beginning January 28, 2023. Twenty-five percent (25%) of the cash-settled share appreciation right will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the cash-settled share appreciation right will vest on a monthly pro-rata basis over the remaining vesting period."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the \"2022 AGM\") of Nabriva Therapeutics plc (the \"Issuer\"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the \"2022 AGM\") of Nabriva Therapeutics plc (the \"Issuer\"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right."}],"balance_after":63200,"derivative":{"exercise_price":0.45,"expiration_date":"2032-01-27","underlying":"Ordinary Shares","underlying_shares":63200},"source":{"system":"sec-edgar","filing":"0001104659-22-091488","document":"tm2222534-17_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1496194/000110465922091488/tm2222534-17_4seq1.xml","form_type":"4"}},{"id":2185621,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":83058,"kind":"person","name":"Naftzger J. Christopher","position":1,"cik":"0001496194","reported_name":"Naftzger J. Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Corp Sec"}}],"security":"Restricted Stock Units","published_at":"2022-08-15T20:39:35.000Z","date":"2022-08-11","kind":"exercise","acquired":false,"shares":31600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The restricted stock units (\"RSU\") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( \"Phantom Shares\"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares."},{"field":"date","element":"transactionDate","label":"F3","text":"The restricted stock units (\"RSU\") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( \"Phantom Shares\"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Subject to the reporting person's continued employment with the Issuer, the Phantom Shares will vest in equal annual installments over four years with the first installment vesting on January 28, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Subject to the reporting person's continued employment with the Issuer, the Phantom Shares will vest in equal annual installments over four years with the first installment vesting on January 28, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The restricted stock units (\"RSU\") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( \"Phantom Shares\"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The restricted stock units (\"RSU\") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( \"Phantom Shares\"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":31600},"source":{"system":"sec-edgar","filing":"0001104659-22-091488","document":"tm2222534-17_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1496194/000110465922091488/tm2222534-17_4seq1.xml","form_type":"4"}},{"id":2185620,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":83058,"kind":"person","name":"Naftzger J. Christopher","position":1,"cik":"0001496194","reported_name":"Naftzger J. Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Corp Sec"}}],"security":"Share Options","published_at":"2022-08-15T20:39:35.000Z","date":"2022-08-11","kind":"exercise","acquired":false,"shares":63200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the \"2022 AGM\") of Nabriva Therapeutics plc (the \"Issuer\"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the \"2022 AGM\") of Nabriva Therapeutics plc (the \"Issuer\"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person's continued employment with the Issuer, the cash-settled share appreciation right will vest over a four-year period beginning January 28, 2023. Twenty-five percent (25%) of the cash-settled share appreciation right will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the cash-settled share appreciation right will vest on a monthly pro-rata basis over the remaining vesting period."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the \"2022 AGM\") of Nabriva Therapeutics plc (the \"Issuer\"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the \"2022 AGM\") of Nabriva Therapeutics plc (the \"Issuer\"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right."}],"balance_after":0,"derivative":{"exercise_price":0.45,"expiration_date":"2032-01-27","underlying":"Ordinary Shares","underlying_shares":63200},"source":{"system":"sec-edgar","filing":"0001104659-22-091488","document":"tm2222534-17_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496194/000110465922091488/tm2222534-17_4seq1.xml","form_type":"4"}},{"id":2419210,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":83058,"kind":"person","name":"Naftzger J. Christopher","position":1,"cik":"0001496194","reported_name":"Naftzger J. Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Corp Sec"}}],"security":"Restricted Stock Units","published_at":"2022-02-01T18:35:27.000Z","date":"2022-01-28","kind":"grant","acquired":true,"shares":31600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The restricted stock units (\"RSU\") were granted on January 28, 2022, and each RSU represents a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval is not obtained, then each RSU will represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date."},{"field":"date","element":"transactionDate","label":"F3","text":"The restricted stock units (\"RSU\") were granted on January 28, 2022, and each RSU represents a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval is not obtained, then each RSU will represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Subject to the reporting person's continued employment with the Issuer, the RSUs will vest in equal annual installments over four years with the first installment vesting on January 28, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Subject to the reporting person's continued employment with the Issuer, the RSUs will vest in equal annual installments over four years with the first installment vesting on January 28, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The restricted stock units (\"RSU\") were granted on January 28, 2022, and each RSU represents a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval is not obtained, then each RSU will represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The restricted stock units (\"RSU\") were granted on January 28, 2022, and each RSU represents a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval is not obtained, then each RSU will represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date."}],"balance_after":31600,"derivative":{"underlying":"Ordinary Shares","underlying_shares":31600},"source":{"system":"sec-edgar","filing":"0001104659-22-010484","document":"tm221371-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1496194/000110465922010484/tm221371-7_4seq1.xml","form_type":"4"}},{"id":2419209,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":83058,"kind":"person","name":"Naftzger J. Christopher","position":1,"cik":"0001496194","reported_name":"Naftzger J. Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Corp Sec"}}],"security":"Share Options","published_at":"2022-02-01T18:35:27.000Z","date":"2022-01-28","kind":"grant","acquired":true,"shares":63200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval is not obtained, the option will remain outstanding and convert into a cash-settled share appreciation right."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the reporting person's continued employment with Nabriva Therapeutics plc (the \"Issuer\"), the option will vest over a four-year period beginning January 28, 2023. Twenty-five percent (25%) of the option will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option will vest on a monthly pro-rata basis over the remaining vesting period."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval is not obtained, the option will remain outstanding and convert into a cash-settled share appreciation right."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval is not obtained, the option will remain outstanding and convert into a cash-settled share appreciation right."}],"balance_after":63200,"derivative":{"exercise_price":0.45,"expiration_date":"2032-01-27","underlying":"Ordinary Shares","underlying_shares":63200},"source":{"system":"sec-edgar","filing":"0001104659-22-010484","document":"tm221371-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496194/000110465922010484/tm221371-7_4seq1.xml","form_type":"4"}},{"id":2457859,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":83058,"kind":"person","name":"Naftzger J. Christopher","position":1,"cik":"0001496194","reported_name":"Naftzger J. Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Corp Sec"}}],"security":"Ordinary Shares","published_at":"2021-12-28T19:04:16.000Z","date":"2021-12-27","kind":"purchase","acquired":true,"shares":7000,"price":0.59,"value":4130.0,"ownership":{"direct":true},"balance_after":7000,"source":{"system":"sec-edgar","filing":"0001104659-21-154012","document":"tm2136401-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496194/000110465921154012/tm2136401-1_4seq1.xml","form_type":"4"}},{"id":2554364,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":83058,"kind":"person","name":"Naftzger J. Christopher","position":1,"cik":"0001496194","reported_name":"Naftzger J. Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and Corp Sec"}}],"security":"Share Option","published_at":"2021-10-01T16:06:38.000Z","date":"2021-09-30","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option was granted on September 30, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest over a four-year period. Twenty-five percent (25%) of the option will vest on the one (1)-year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option will vest on an annual pro-rata basis over the remaining vesting period."}],"balance_after":100000,"derivative":{"exercise_price":1.19,"expiration_date":"2031-09-29","underlying":"Ordinary Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-21-121964","document":"tm2129004-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496194/000110465921121964/tm2129004-1_4seq1.xml","form_type":"4"}}]}